Kiniksa Pharmaceuticals, Ltd. logo
Kiniksa Pharmaceuticals, Ltd. KNSA
$ 22.59 -1.83%

Quarterly report 2024-Q3
added 10-29-2024

report update icon

Kiniksa Pharmaceuticals, Ltd. Balance Sheet 2011-2024 | KNSA

Annual Balance Sheet Kiniksa Pharmaceuticals, Ltd.

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-95.7 M -117 M -116 M -107 M -46.9 M -72 M -45.6 M -56 M - - - - -

Long Term Debt

10 M 2.62 M 2.67 M 4.88 M - - - - - - - - -

Long Term Debt Current

2.25 M 3.3 M 3.38 M 2.11 M 1.7 M - - - - - - - -

Total Non Current Liabilities

- - - - 1.28 M 144 K 120 M 79.9 M - - - - -

Total Current Liabilities

63.7 M 47.1 M 44.8 M 31.8 M 27.8 M 42.6 M - - - - - - -

Total Liabilities

87.5 M 63.5 M 47.8 M 37.5 M 29.1 M 42.7 M 137 M 82.2 M - - - - -

Deferred Revenue

307 K - - - - - - - - - - - -

Retained Earnings

-478 M -492 M -675 M -517 M -356 M -194 M -91 M -26.1 M - - - - -

Total Assets

526 M 460 M 233 M 349 M 255 M 322 M 47.5 M 56.5 M - - - - -

Cash and Cash Equivalents

108 M 123 M 122 M 114 M 46.9 M 72 M 45.7 M - - - - - -

Book Value

439 M 396 M 185 M 312 M 225 M 279 M -89.7 M -25.7 M - - - - -

Total Shareholders Equity

439 M 396 M 185 M 312 M 225 M 279 M -89.7 M - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Kiniksa Pharmaceuticals, Ltd.

2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

8.56 M 9.32 M 9.86 M 10.7 M 11.3 M 2.13 M 2.62 M 3.44 M - 2.1 M 2.67 M 3.5 M 3.5 M 4.2 M 4.88 M 4.88 M 4.88 M 4.88 M 955 K 955 K 955 K 955 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

118 M 107 M 87.8 M 77.9 M 72.7 M 52.8 M 63.5 M 75.9 M - 64.7 M 47.8 M 38.8 M 43.4 M 40.5 M 37.5 M 37.5 M 37.5 M 37.5 M 29.1 M 29.1 M 29.1 M 29.1 M 42.7 M 42.7 M 42.7 M 42.7 M 17.4 M 17.4 M 17.4 M - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- 12 K 156 K 2.56 M 4.67 M 6.5 M - 12.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-512 M -500 M -496 M -503 M -489 M -504 M -492 M -496 M - -701 M -675 M -639 M -609 M -567 M -517 M -517 M -517 M -517 M -356 M -356 M -356 M -356 M -194 M -194 M -194 M -194 M -91 M -91 M -91 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

555 M 542 M 520 M 483 M 484 M 443 M 460 M 460 M - 231 M 233 M 253 M 279 M 311 M 349 M 349 M 349 M 349 M 255 M 255 M 255 M 255 M 322 M 322 M 322 M 322 M 47.5 M 47.5 M 47.5 M - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

97.4 M 99.3 M 141 M 118 M 113 M 80.6 M 123 M 176 M 94.3 M 63.3 M 122 M 190 M 168 M 120 M 114 M 114 M 114 M 114 M 46.9 M 46.9 M 46.9 M 46.9 M 72 M 72 M 72 M 72 M 45.6 M 45.6 M 45.6 M - 56.1 M - - - - - - - - - - - - - - - - - - - - - - -

Book Value

437 M 435 M 432 M 405 M 412 M 390 M 396 M 384 M - 166 M 185 M 214 M 236 M 271 M 312 M 312 M 312 M 312 M 225 M 225 M 225 M 225 M 279 M 279 M 279 M 279 M 30.1 M 30.1 M 30.1 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

437 M 435 M 432 M 405 M 412 M 390 M 396 M 384 M 153 M 166 M 185 M 214 M 236 M 271 M 312 M 312 M 312 M 312 M 225 M 225 M 225 M 225 M 279 M 279 M 279 M 279 M -89.7 M -89.7 M -89.7 M - -25.7 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency